Antiviral compounds

Details Antiviral compounds Antiviral compounds

2002-05-02

2009-10-13

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S012200, C514S043000, C514S894000

Reexamination Certificate

active

07601735

ABSTRACT:
Use of certain castanospermine esters in the treatment of diseases caused by flaviviruses, in particular in the treatment of disease caused by the hepatitis C virus (HCV) and compositions containing said esters in combination with adjunctive therapeutic agents.

REFERENCES:
patent: 4849430 (1989-07-01), Fleet et al.
patent: 4970317 (1990-11-01), Margolin et al.
patent: 5004746 (1991-04-01), Liu et al.
patent: 5066807 (1991-11-01), Anzeveno et al.
patent: 5093501 (1992-03-01), Anzeveno et al.
patent: 5385911 (1995-01-01), Sunkara et al.
patent: 5939430 (1999-08-01), Tyms et al.
patent: 5959111 (1999-09-01), Goralski et al.
patent: 297534 (1994-12-01), None
patent: WO 99/29321 (1999-06-01), None
patent: WO 01/54692 (2001-08-01), None
Michael, Joseph P., “Indolizidine and Quinolizidine Alkaloids,” Natural Product Reports, 1997, p. 619-636.
Norwegian Office Action dated Feb. 22, 2007, which issued for Norwegian Patent Application No. 20034878.
Dubuisson, J. et al., “Glycosylation of the Hepatitis C Virus Envelope Protein E1 Is Dependent on the Prescence of a Downstream Sequence on the Viral Polyprotein,”The Journal of Biological Chemistry 275(39): 30605-30609, 2000.
Dubuisson and Rice, “Hepatitis C Virus Glycoprotein Folding: Disulfide Bond Formation and Association with Calnexin,”Journal of Virology 70(2): 778-786, Feb. 1996.
Chan-Fook, C. et al., “Hepatitis C Virus Glycoprotein E2 Binding to CD81: The Role of E1E2 Cleavage and Protein Glycosylation in Bioactivity,”Virology 273(1): 60-66, Jul. 20, 2000.
Meunier, J-C. et al., “Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex,”Journal of General Virology 80:887-896, 1999.
Blight, K.J. et al., “Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets,”Antiviral Therapy 3(Supplement 3): 71-81, 1998.
Dubuisson, J. et al., “Assembly of Hepatitis C virus glycoproteins,”Recent Research Developments in Virology, vol. 1, Part 1, Pandalai, S.G. (ed.), Transworld Research Network, Trivandrum, India, 1999, pp. 29-39.
Ruprecht, R.M. et al., “In Vivo Analysis of Castanospermine, a Candidate Antiretroviral Agent,”Journal of Acquired Immune Deficiency Syndromes 2(2): 149-157, 1989.
Sunkara, P.S. et al., “Inhibition of Glycoprotein Processing and HIV Replication by Castanospermine Analogues,”Annals of the New York Academy of Sciences 616: 90-96, 1990.
Dettenhofer and Yu, “Characterization of the Biosynthesis of Human Immunodeficiency Virus Type 1 Env from Infected T-cells and the Effects of Glucose Trimming of Env on Virion Infectivity,”The Journal of Biological Chemistry 276(8): 5985-5991, Feb. 23, 2001.
Ahmed, S.P. et al., “Antiviral Activity and Metabolism of the Castanospermine Derivative MDL 28,574, in Cells Infected with Herpes Simplex Virus Type 2,”Biochemical and Biophysical Research Communications 208(1): 267-273, Mar. 8, 1995.
Bridges, C.G. et al., “The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection,”Glycobiology 5(2): 249-253, 1995.
Zitzmann, N. et al., “Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents,”Proc. Natl. Acad. Sci. USA 96(21): 11878-11882, Oct. 12, 1999.
Block, et al., PNAS 91:2235-2239) (1994), “Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar N-butyldeoxynojirimycin”.
Blough, et al. Biochemical and Biophysical Research Communications (141(1), 33-38 (1986), “Glycosylation Inhibitors Block the Expression of LAV/HTLV-III(HIV)Glycoproteins”.
McDowell, et al., Biochemistry, 34(27), 8145-52 (1985), “Mechanism of Inhibition of Protein Glycosylation by the Antiviral Sugar Analogue 2-Deoxy-2-fluoro-D-mannose: Inhibition of Synthesis of Man(GIcNAc)2—PP Dol by the Guanosine Diphosphate Ester”.
Lu, et al., Virology 213:660-665 (1995), “Evidence that the N-Linked Glycosylation is Necessary for Hepatitis B Virus Secretion”.
Sunkara, et al., Lancet II 1206 (1989), “Anti-HIV Activity of Castanospermine Analogues”.
Kang et al.; Castanospermine analogues: their inhibition of glycoprotein processing α-glucosidases from porcine kidney and B16F10cells; Glycobiology; 1995; 147-152; Oxford University Press.
Kang, “Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug,”Glycobiology 6(2): 209-216, 1996.
Taylor et al., Antiviral Res. 10:11-26 (1988), “Loss of Cytomegalovirus Infectivity After Treatment with Castanospermine . . .”.
Taylor et al., Antimicrob. Ag. Chemother. 38:1780-1787 (1994), “Inhibition of α-Glucosidase I of the Glycoprotein-Processing Enzymes . . .”.
Branza-Nichita et al., J. Virol. 75(8):3527-3536 (2001), “Antiviral Effect of N-Butyldeoxynojirimycin against Bovine Viral Diarrhea . . .”.
Courageot et al., J. Virol. 74(1):564-572 (2000), “α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis . . .”.
Choukhi et al., J. Virol., 72(5):3851-3858 (1998), “Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins”.

Affiliated with

Also associated with

Rating

Antiviral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4097233